about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

En­cour­ag­ing gene ther­a­py da­ta give uniQure an in­jec­tion of con­fi­dence as it preps PhI­II show­down with Spark

7 years ago
R&D
Cell/Gene Tx

Re­searchers spot­light a bas­ket of 'good' re­sponse rates for the next ADC in Seat­tle Ge­net­ic­s' pipeline

7 years ago
R&D

Tight­en­ing its wal­let for a clin­i­cal come­back, Seres lets go of CSO and 30% of work­force

7 years ago
R&D

Al­ny­lam shores up en­thu­si­asm for givosir­an with ear­ly dataset ahead of cru­cial PhI­II read­out

7 years ago
R&D

Split up the chair­man/CEO role at Al­ler­gan — ac­tivist in­vestor; Zo­genix files for FDA, EMA ap­proval of seizure drug

7 years ago
News Briefing

A 'dis­ori­ent­ed' Pain Ther­a­peu­tics flips out af­ter FDA re­jects ap­peal on Re­moxy

7 years ago
R&D

Here come the 2019 uni­corns: Alec­tor, Gos­samer set to launch IPOs don­ning $1B-plus mar­ket caps

7 years ago
Financing

Ke­to in a pill? Jim Mel­lon de­buts an­ti-ag­ing joint ven­ture with the Buck ded­i­cat­ed to in­duc­ing ke­to­sis

7 years ago
Startups

Evo­lus cel­e­brates green­light for Botox ri­val while Al­ler­gan coun­ter­at­tacks with a com­plaint of stolen trade se­crets

7 years ago
Pharma

Richard Pas­coe takes the helm at His­to­gen; Lon­za COO steps up at CEO Richard Ridinger re­tires

7 years ago
Peer Review

Alex­ion lines up a $60M op­tion to buy Fortress-in­cu­bat­ed biotech fo­cused on a lu­cra­tive rare blood dis­ease

7 years ago
Pharma

Path to the top: What kind of ex­pe­ri­ence does it take to get tapped for the helm of a biotech?

7 years ago
People
In Focus

Roche pulls an­oth­er ma­jor piece out of the wob­bly Alzheimer's jen­ga, shut­ter­ing crenezum­ab PhI­I­Is

7 years ago
R&D

Take­da claims PhI­II suc­cess in dengue vac­cine months af­ter Deng­vax­ia im­plo­sion for ri­val Sanofi

7 years ago
R&D

Cel­gene rolls along with an­oth­er epi­ge­net­ic pre­clin­i­cal deal fea­tur­ing a Cana­di­an biotech

7 years ago
Discovery

Un­fazed by Brex­it blues, UK biotech trade group cel­e­brates bois­ter­ous year of ven­ture dol­lars with record £1.1B ...

7 years ago
Financing

A stem cell ther­a­py preps de­but in Japan­ese mar­ket to the dis­may of US re­searchers

7 years ago
Cell/Gene Tx

Ver­tex COO Ian Smith oust­ed due to 'per­son­al be­hav­ior'; CFO Mats Blom ex­its Zealand Phar­ma; Ka­trine Bosley abrupt­ly ...

7 years ago
Peer Review

In an­oth­er set­back for Eli Lil­ly, FDA fol­lows EMA in call­ing for a halt to new Lartru­vo pre­scrip­tions

7 years ago
Pharma

FDA opi­oid ad­comm chair blasts agency for 'will­ful blind­ness that bor­ders on the crim­i­nal'

7 years ago
Pharma

Mass cloning for neu­ro re­search? Chi­nese sci­en­tists re­port birth of five gene-edit­ed mon­keys

7 years ago
China
Discovery

Turn­ing the ta­ble on CD47, Penn team primes macrophages to ig­nore 'don't eat me' sig­nal

7 years ago
Discovery

Mi­cro­bio­me, in­flam­ma­tion and mu­ta­tions: US re­searchers win £60M in Can­cer Re­search UK grants to lead 'grand ...

7 years ago
R&D

No­vo in­fus­es cash in­to 4 biotechs, adding to their ar­se­nal for the su­per­bugs bat­tle to come

7 years ago
Financing
First page Previous page 104105106107108109110 Next page Last page
A service from the Financial Times